Persistent defect in regulation of prolactin secretion after successful pituitary tumor removal in women with the galactorrhea-amenorrhea syndrome.
TRH, metoclopramide (MCP), chlorpromazine (CPZ), and insulin (ITT) stimulation tests of PRL secretion were carried out in age-matched controls and before and after successful removal of pituitary prolactinomas in women with the galactorrhea-amenorrhea syndrome. In preoperative patients there was a blunted or absent PRL response to TRH in 87%, to MCP in 100%, to CPZ in 100%, and to ITT in 93%. Two to 6 months after successful tumor removal, serum PRL rose 2-fold (the usual criterion for a normal response) in 73% after TRH, in 100% after MCP, but in only 13% after CPZ and in only 14% on ITT. However, the PRL increment with all four tests was significantly lower than that in normal controls. One to 8 yr after successful surgery, the PRL increments after TRH and MCP were returning to normal, but the PRL responses to CPZ and ITT remained blunted. GH, ACTH, and TSH reserves were intact in all patients. The diminished PRL response to all stimulation tests observed up to 6 months postoperatively might be explained by the persistence of a negative feedback effect from high PRL levels associated with the tumor. The more persistent impairment of the PRL response to CPZ and ITT is unexplained but suggests a hypothalamic defect.
D000568:Amenorrhea / Q000150:complications / Q000503:physiopathology*; D002746:Chlorpromazine; D005260:Female; D005687:Galactorrhea / Q000150:complications / Q000503:physiopathology*; D006801:Humans; D007328:Insulin; D007775:Lactation Disorders / Q000503:physiopathology*; D008787:Metoclopramide; D010911:Pituitary Neoplasms / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone
D007328:Insulin; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D008787:Metoclopramide; D002746:Chlorpromazine